Ligand Pharma (LGND) Tops Q2 EPS by 141c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $296.90 +0.78%
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Decrease (increase) in liability for contingent value rights: -958K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
- Ligand Pharma (LGND) Reiterated at Buy by Stifel After Chat With CEO, CFO
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
